Weight Loss, Obesity Medication, and Risk of Obesity‐Associated Cancer: A Meta‐Analysis of Randomized Controlled Trials
Obesity · 2026-09 · 34 (S2) · 16-24
DOI: 10.1002/oby.70054 ↗At a glance
Metaanalyse in Obesity, published online on 2025-11-04. Written by Chengwen Li and 5 co-authors. Institution: Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China. Major MEDLINE topics: Anti-Obesity Agents, Neoplasms, Obesity, Weight Loss. Cited 2 times so far (Crossref); 46 references. The full text is freely available in PubMed Central. Funded by: Clinical Medicine Plus X-Young Scholars Project of Peking University, Fundamental Research Funds for the Central Universities, Noncommunicable Chronic Diseases-National Science and Technology Major Project.
Abstract (original language)
Objective
This study aimed to determine whether weight reduction mediated by antiobesity medications (AOMs) contributes to the risk reduction in obesity‐associated cancer.
Methods
PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and the ClinicalTrials.gov website were systematically searched for randomized controlled trials of AOMs from inception to December 2024. Relative risks were calculated using a random‐effects model.
Results
The analysis included 25 randomized controlled trials with 40,731 participants. Compared with placebo, AOMs showed no association with the risk of overall obesity‐related cancer (RR = 1.03, 95% CI: 0.78 to 1.37) or site‐specific cancer. Consistently, every 5 kg weight reduction mediated by AOMs was not associated with the risk of overall obesity‐related cancer (RR = 0.97, 95% CI: 0.84 to 1.12) or site‐specific cancer. However, subgroup analysis revealed that coagonists (tirzepatide, cotadutide, and cagrilintide) significantly reduced overall obesity‐associated cancer risk (RR = 0.43, 95% CI: 0.19 to 0.97), and every 5 kg weight reduction mediated by coagonists was marginally associated with a reduced overall obesity‐associated cancer risk (RR = 0.79, 95% CI: 0.62 to 1.00).
Conclusions
Weight reduction mediated by current AOMs was not associated with a reduced risk of overall or site‐specific obesity‐associated cancer in patients with overweight or obesity, while a decreased risk of overall obesity‐associated cancer was observed in coagonist users.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
ORCID profiles: Chengwen Li, Chu Lin, Xiaoling Cai, Fang Lv, Linong Ji
Funding
- Clinical Medicine Plus X-Young Scholars Project of Peking University
- Fundamental Research Funds for the Central Universities
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- 2024 National Clinical Key Specialty Construction Program of China
Cite
APA
Li, C., Lin, C., Cai, X., Lv, F., Yang, W., & Ji, L. (2026). Weight Loss, Obesity Medication, and Risk of Obesity‐Associated Cancer: A Meta‐Analysis of Randomized Controlled Trials. Obesity, 34(S2), 16-24. https://doi.org/10.1002/oby.70054
Vancouver
Li C, Lin C, Cai X, Lv F, Yang W, Ji L. Weight Loss, Obesity Medication, and Risk of Obesity‐Associated Cancer: A Meta‐Analysis of Randomized Controlled Trials. Obesity. 2026;34(S2):16-24. doi:10.1002/oby.70054
BibTeX
@article{Li2026,
author = {Li, Chengwen and Lin, Chu and Cai, Xiaoling and Lv, Fang and Yang, Wenjia and Ji, Linong},
title = {Weight Loss, Obesity Medication, and Risk of Obesity‐Associated Cancer: A Meta‐Analysis of Randomized Controlled Trials},
journal = {Obesity},
year = {2026},
volume = {34},
number = {S2},
pages = {16--24},
doi = {10.1002/oby.70054}
}
EUVIMED